NCT01749397View on ClinicalTrials.gov

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

October 20, 2017

Study Completion Date

November 21, 2019

Conditions

Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

DRUG

Floxuridine

Given IP

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given IV

Trial Locations (5)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

55905

Mayo Clinic in Rochester, Rochester

63110

Siteman Cancer Center at Washington University, St Louis

Washington University School of Medicine, St Louis

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01749397 - Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter